30 patents
Utility
Composition or method including (t)ew-7197 for treating or preventing corneal endothelial diseases
2 Jan 24
The present disclosure provides a composition for treating or preventing symptoms, disorders, or diseases of the corneal endothelium.
Noriko Koizumi, Naoki Okumura, Mayumi Yamamoto
Filed: 13 Dec 18
Utility
Composition for treatment and/or prevention of peripheral nerve disorder
19 Dec 23
Shinji Hirotsune
Filed: 22 May 17
Utility
Agent for promoting corneal endothelial cell adhesion
12 Dec 23
The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.
Noriko Koizumi, Shigeru Kinoshita, Morio Ueno
Filed: 9 Oct 15
Utility
Therapeutic Agent for COVID-19
7 Dec 23
The present invention aims to develop a method for treating COVID-19 caused by SARS-CoV-2 or a mutant strain thereof, and provides an agent for preventing and/or treating COVID-19 caused by SARS-CoV-2 or a mutant strain thereof, the agent comprising a specific compound.
Mitsuyoshi AZUMA, Chiho FUKIAGE, Takashi IMADA, Yayoi KISHIMOTO, Noriyasu HIRASAWA, Yoshiro SAITO, Takashi TOYAMA
Filed: 29 Oct 21
Utility
Corneal Endothelium Ecm Therapeutic Medicaments
5 Oct 23
The present invention provides medicaments for treating or preventing a disease, disorder, or condition associated with extracellular matrix (ECM) abnormality in a corneal endothelium, wherein the medicaments comprise a TGF-beta signal inhibiting agent.
Noriko KOIZUMI, Naoki OKUMURA, Shigeru KINOSHITA
Filed: 7 Jun 23
Utility
Corneal endothelium ECM therapeutic medicaments
22 Aug 23
The present invention provides medicaments for treating or preventing a disease, disorder, or condition associated with extracellular matrix (ECM) abnormality in a corneal endothelium, wherein the medicaments comprise a TGF-beta signal inhibiting agent.
Noriko Koizumi, Naoki Okumura, Shigeru Kinoshita
Filed: 30 Jul 13
Utility
Agent for Promoting Corneal Endothelial Cell Adhesion
6 Jul 23
The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.
Noriko KOIZUMI, Shigeru KINOSHITA, Morio UENO
Filed: 13 Mar 23
Utility
Bodily Fluid Collecting Device
4 May 23
Provided are a bodily fluid-collecting device that is capable of collecting a fixed amount of bodily fluid while minimizing damage to a living body, a method for collecting a bodily fluid using the device, and a method for collecting an aqueous humor using the device A bodily fluid-collecting device 1 comprises a needle part 2 having a needle tube 3 with a needle tip 32, and a capillary 5 removably connected to a base end part 33 of the needle tube 3 in its longitudinal direction on a side opposite to the needle tip 32.
Ryo YOSHINAGA, Tatsuya SAKAI
Filed: 26 Mar 21
Utility
Agent for promoting corneal endothelial cell adhesion
25 Apr 23
The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.
Noriko Koizumi, Shigeru Kinoshita, Morio Ueno
Filed: 9 Oct 15
Utility
Treatment of cornea using laminin
25 Apr 23
The present invention provides a technique for treating the cornea.
Noriko Koizumi, Naoki Okumura, Shigeru Kinoshita
Filed: 30 Oct 15
Utility
Use of Polyether Compound
30 Mar 23
The present disclosure provides the use of a polyether compound.
Noriaki NISHIDA
Filed: 2 Feb 21
Utility
NRF2-ACTIVATING Compound
26 Jan 23
Tomoyo MIYABE, Shinnosuke MACHIDA, Yuka OBA
Filed: 3 Jul 20
Utility
Pharmaceutical Drug Containing Heterocyclidene Acetamide Derivative
24 Nov 22
This disclosure provides a means for treating dry eye.
Takeshi TARUI, Shinya KOBAYASHI
Filed: 2 Oct 20
Utility
Novel Use of Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR)
24 Nov 22
The present disclosure provides a novel use of nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR).
Masao Doi, Takeshi Nakajima, Mamiko Machida
Filed: 24 Jun 20
Utility
Therapeutic Drug for Diseases Related to Endoplasmic Reticulum Cell Death In Corneal Endothelium
22 Sep 22
The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress.
Noriko KOIZUMI, Naoki OKUMURA, Shigeru KINOSHITA
Filed: 3 Jun 22
Utility
Emulsion eyedrops
13 Sep 22
Provided are: emulsion eyedrops which have no concern with possible corneal injury induced by a nonionic surfactant, have excellent thermal stability and physical stability and can contain a sparingly water-soluble drug in an increased amount; and an emulsion eyedrops stabilization method.
Yasuhiro Mori
Filed: 16 Nov 17
Utility
Eye Disease Marker
14 Jul 22
The present disclosure provides a marker that shows a relationship with changes in the nerve density and morphology in the cornea.
Jun SHIMAZAKI
Filed: 24 Apr 20
Utility
Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
12 Jul 22
The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress.
Noriko Koizumi, Naoki Okumura, Shigeru Kinoshita
Filed: 30 Oct 14
Utility
Composition for Preventing or Treating Neurotrophic Keratitis Which Contains Pacap Peptide or Stabilized Pacap Peptide
30 Jun 22
The purpose of the present invention is to provide a composition for preventing or treating neurotrophic keratitis.
Takeshi NAKAJIMA, Mamiko MACHIDA, Shuhei YAMADA
Filed: 14 May 20
Utility
Retinal Ganglion Cell Death Inhibitor
11 Nov 21
The present invention relates to a retinal ganglion cell death suppressor comprising a BMPR signal transduction inhibitor, a drug comprising a BMPR signal transduction inhibitor for protecting retinal neurons, and a pharmaceutical composition using these for preventing or treating a disease involving retinal ganglion cell death, such as glaucoma, diabetic retinopathy and retinal vascular occlusion.
Yayoi KISHIMOTO, Chiho YABUTA
Filed: 28 Oct 19